FORA Capital LLC Purchases New Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

FORA Capital LLC purchased a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the fourth quarter, Holdings Channel reports. The firm purchased 7,797 shares of the specialty pharmaceutical company’s stock, valued at approximately $223,000.

Several other institutional investors also recently bought and sold shares of COLL. Deutsche Bank AG grew its position in shares of Collegium Pharmaceutical by 12.2% in the fourth quarter. Deutsche Bank AG now owns 84,163 shares of the specialty pharmaceutical company’s stock valued at $2,411,000 after purchasing an additional 9,164 shares during the period. Centiva Capital LP purchased a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $307,000. BOKF NA boosted its stake in shares of Collegium Pharmaceutical by 25.2% in the fourth quarter. BOKF NA now owns 16,923 shares of the specialty pharmaceutical company’s stock worth $485,000 after acquiring an additional 3,403 shares during the last quarter. Brevan Howard Capital Management LP purchased a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth approximately $281,000. Finally, Freestone Grove Partners LP acquired a new position in Collegium Pharmaceutical in the 4th quarter valued at $319,000.

Wall Street Analysts Forecast Growth

Several research firms recently commented on COLL. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a report on Monday, March 24th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 19th. Needham & Company LLC reiterated a “buy” rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Finally, Piper Sandler restated a “neutral” rating and set a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.80.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $28.89 on Friday. The stock’s 50-day moving average is $28.10 and its two-hundred day moving average is $30.03. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a market cap of $928.29 million, a price-to-earnings ratio of 12.45 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 1,949 shares of the company’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total value of $58,470.00. Following the completion of the transaction, the chief financial officer now owns 177,195 shares in the company, valued at $5,315,850. This represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Scott Dreyer sold 2,255 shares of the firm’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the transaction, the executive vice president now directly owns 124,421 shares in the company, valued at approximately $3,732,630. The trade was a 1.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 81,693 shares of company stock worth $2,334,994 over the last 90 days. 2.51% of the stock is owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.